Combination therapy with Fasudil and Sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats

Circulation Journal

Volumn 78, Issue 4, 2014, Pages 967-976

  Elias Al Mamun, Md ^a   Satoh, Kimio ^a   Tanaka, Shin Ichi ^a   Shimizu, Toru ^a   Nergui, Suvd ^a   Miyata, Satoshi ^a   Fukumoto, Yoshihiro ^a   Shimokawa, Hiroaki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Combination therapy; Fasudil; Hypertrophy; Pulmonary hypertension; Sildenafil

Indexed keywords

FASUDIL; RHO KINASE; SILDENAFIL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; CELL PROLIFERATION; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART RIGHT VENTRICLE HYPERTROPHY; HISTOLOGY; HYPERTROPHY; MALE; MORPHOMETRICS; NONHUMAN; PH; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONES;

EID: 85047688709     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1174     Document Type: Article

References (61)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-1436.
2. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
3. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012; 122: 4306-4313.
4. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006; 114: 1417-1431.
5. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 13S-24S.
6. Satoh K, Kagaya Y, Nakano M, Ito Y, Ohta J, Tada H, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006; 113: 1442-1450.
7. Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Car-diol 2008; 51: 1527-1538.
8. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131: 1917-1928.
9. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
10. Amano M, Chihara K, Kimura K, Fukata Y, Nakamura N, Matsuura Y, et al. Formation of actin stress fbers and focal adhesions enhanced by Rho-kinase. Science 1997; 275: 1308-1311.
11. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 1996; 15: 1885-1893.
12. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: Important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2011; 301: H287-H296.
13. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
14. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
15. Hall A. Rho GTPases and the Actin Cytoskeleton. Science 1998; 279: 509-514.
16. Chihara K, Amano M, Nakamura N, Yano T, Shibata M, Tokui T, et al. Cytoskeletal rearrangements and transcriptional activation of c-fos serum response element by Rho-kinase. J Biol Chem 1997; 272: 25121-25127.
17. Narumiya S. The small GTPase Rho: Cellular functions and signal transduction. J Biochem 1996; 120: 215-228.
18. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011; 75: 1801-1810.
19. Fukumoto Y, Tawara S, Shimokawa H. Recent progress in the treatment of pulmonary arterial hypertension: Expectation for Rho-kinase inhibitors. Tohoku J Exp Med 2007; 211: 309-320.
20. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: Promising new target in cardiovascular therapy. Circ J 2010; 74: 2249-2256.
21. Abe K, Tawara S, Oi K, Hizume T, Uwatoku T, Fukumoto Y, et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol 2006; 48: 280-285.
22. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol 2004; 287: L665-L672.
23. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004; 94: 385-393.
24. Do e Z, Fukumoto Y, Takaki A, Tawara S, Ohashi J, Nakano M, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J 2009; 73: 1731-1739.
25. Satoh K, Fukumoto Y, Sugimura K, Miura Y, Aoki T, Nochioka K, et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J 2013; 77: 447-455.
26. Fukumoto Y, Yamada N, Matsubara H, Mizoguchi M, Uchino K, Yao A, et al. Double-blind, placebo-controlled clinical trial with a Rho-kinase inhibitor in pulmonary arterial hypertension: A pilot effcacy trial. Circ J 2013; 77: 2619-2625.
27. Zeng Z, Li Y, Jiang Z, Wang C, Li B, Jiang W. The extracellular signal-regulated kinase is involved in the effects of sildenafl on pulmonary vascular remodeling. Cardiovasc Ther 2010; 28: 23-29.
28. Kuang T, Wang J, Pang B, Huang X, Burg ED, Yuan JX, et al. Combination of sildenafl and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. Pulm Pharmacol Ther 2010; 23: 456-464.
29. Guilluy C, Sauzeau V, Rolli-Derkinderen M, Guerin P, Sagan C, Pacaud P, et al. Inhibition of RhoA/Rho kinase pathway is involved in the benefcial effect of sildenafl on pulmonary hypertension. Br J Pharmacol 2005; 146: 1010-1018.
30. Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007; 50: 195-200.
31. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008; 3: 1422-1434.
32. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al. A combination of oral sildenafl and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 34-38.
33. Urboniene D, Haber I, Fang YH, Thenappan T, Archer SL. Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fdelity catheterization in experimental pulmonary hypertension. Am J Physiol 2010; 299: L401-L412.
34. Mouchaers KT, Schalij I, de Boer MA, Postmus PE, van Hinsbergh VW, van Nieuw Amerongen GP, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: Comparison with bosentan and sildenafl. Eur Respir J 2010; 36: 800-807.
35. Jung SM, Park SS, Kim WJ, Moon SK. Ras/ERK1 pathway regulation of p27KIP1-mediated G1-phase cell-cycle arrest in cordycepin-induced inhibition of the proliferation of vascular smooth muscle cells. Eur J Pharmacol 2012; 681: 15-22.
36. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylgl-utaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
37. 2+ signaling in hypoxic pulmonary vasoconstriction: Effects of myosin light chain and Rho kinase antagonists. Am J Physiol 2007; 293: L674-L685.
38. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, et al. Sildenafl inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-428.
39. Dohi K, Onishi K, Gorcsan J 3rd, Lopez-Candales A, Takamura T, Ota S, et al. Role of radial strain and displacement imaging to quantify wall motion dyssynchrony in patients with left ventricular mechanical dyssynchrony and chronic right ventricular pressure overload. Am J Cardiol 2008; 101: 1206-1212.
40. Jiang BH, Tawara S, Abe K, Takaki A, Fukumoto Y, Shimokawa H. Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in mono-crotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007; 49: 85-89.
41. Clozel M, Hess P, Rey M, Iglarz M, Binkert C, Qiu C. Bosentan, sildenafl, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med 2006; 231: 967-973.
42. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, et al. Right ventricular function and failure: Report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006; 114: 1883-1891.
43. Schafer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. Cardiovasc Res 2009; 82: 30-39.
44. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012; 40: 1555-1565.
45. Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, et al. Protein kinase A as another mediator of ischemic preconditioning independent of protein kinase C. Circulation 2004; 110: 51-57.
46. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, et al. Inhibition of Rho-kinase leads to rapid activation of phospha-tidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol 2004; 24: 1842-1847.
47. Demiryurek S, Kara AF, Celik A, Babul A, Tarakcioglu M, Demiryurek AT. Effects of fasudil, a Rho-kinase inhibitor, on myocardial preconditioning in anesthetized rats. Eur J Pharmacol 2005; 527: 129-140.
48. Bao W, Hu E, Tao L, Boyce R, Mirabile R, Thudium DT, et al. Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovasc Res 2004; 61: 548-558.
49. Kukreja RC. Cardiovascular protection with sildenafl following chronic inhibition of nitric oxide synthase. Br J Pharmacol 2007; 150: 538-540.
50. Rossoni G, Manfredi B, De Gennaro Colonna V, Berti M, Guazzi M, Berti F. Sildenafl reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 2007; 150: 567-576.
51. Nagy O, Hajnal A, Parratt JR, Vegh A. Sildenafl (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol 2004; 141: 549-551.
52. Kukreja RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A, et al. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy. J Mol Cell Cardiol 2004; 36: 165-173.
53. Nakamura K, Shimizu J, Kataoka N, Hashimoto K, Ikeda T, Fujio H, et al. Altered nano/micro-order elasticity of pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2010; 140: 102-107.
54. Gudi T, Chen JC, Casteel DE, Seasholtz TM, Boss GR, Pilz RB. CGMP-dependent protein kinase inhibits serum-response element-dependent transcription by inhibiting Rho activation and functions. J Biol Chem 2002; 277: 37382-37393.
55. Rikitake Y, Liao JK. Rho GTPases, statins, and nitric oxide. Circ Res 2005; 97: 1232-1235.
56. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62.
57. Liu AJ, Ling F, Wang D, Wang Q, and Lu XD, Liu YL. Fasudil inhibits platelet-derived growth factor-induced human pulmonary artery smooth muscle cell proliferation by up-regulation of p27kip1 via the ERK signal pathway. Chin Med J 2011; 124: 3098-3104.
58. Wang N, Guan P, Zhang JP, Li YQ, Chang YZ, Shi ZH, et al. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses isoproter-enol-induced heart failure in rats via JNK and ERK1/2 pathways. J Cell Biochem 2011; 112: 1920-1929.
59. Chen XY, Dun JN, Miao QF, Zhang YJ. Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, suppresses 5-hydroxytryptamine-induced pulmonary artery smooth muscle cell proliferation via JNK and ERK1/2 pathway. Pharmacology 2009; 83: 67-79.
60. Li B, Yang L, Shen J, Wang C, Jiang Z. The antiproliferative effect of sildenafl on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phos-phorylation. Anesth Analg 2007; 105: 1034-1041.
61. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, et al. Antiproliferative effect of sildenafl on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131-138.